Large investor in Esperion Therapeutics buys $2 million in additional shares
Biotech Target NV, who already control 10% of shares at Esperion Therapeutics (ESPR), bought 50,000 additional shares of the company’s common stock on Dec 24. At $39.91 per share, Biotech Target NV paid a total of $1,995,725 for the new shares.
Already a member?
Login to see your Insider Activity Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.